ABSTRACT
BACKGROUND: Most paediatric tuberculosis (TB) cases in low-TB-incidence countries involve children born to migrant families. This may be partially explained by trips to their countries of origin for visiting friends and relatives (VFR). We aimed to estimate the risk of latent TB infection (LTBI) and TB in children VFR. METHODS: We conducted a prospective multicentric observational study in Catalonia (Spain) from 06/2017 to 12/2019. We enrolled children aged < 15 years with a negative tuberculin skin test (TST) at baseline and at least one parent from a high-TB-incidence country, and who had travelled to their parent's birth country for ≥21 days. TST and QuantiFERON-TB Gold Plus (QFT-Plus) were performed within 8-12 weeks post-return. LTBI was defined as a TST ≥5 mm and/or a positive QFT-Plus. RESULTS: Five hundred children completed the study, equivalent to 78.2 person-years of follow-up (PYFU). Thirteen children (2.6%) were diagnosed with LTBI (16.6/per100 PYFU,95%CI = 8.8-28.5), including two cases (0.4%) of TB (2.5/per100 PYFU, 95%CI = 0.3-9.3). LTBI incidence rates remained high after excluding BCG-vaccinated children (9.7/per100 PYFU,95%CI = 3.9-20.0). Household tobacco smoke exposure was associated with LTBI (aOR = 3.9, 95%CI = 1.1-13.3). CONCLUSIONS: The risk of LTBI in children VFR in high-TB-incidence countries may equal, or perhaps even exceed, the infection risk of the native population. The primary associated risk factor was the presence of smokers in the household. Furthermore, the incidence rate of active TB largely surpassed that of the countries visited. Children VFR in high-TB-incidence countries should be targeted for diagnostic and preventive interventions.
ABSTRACT
Más de un millón de pacientes menores de 15 años desarrollan tuberculosis (TB) anualmente en el mundo, según estimaciones de la OMS. La TB por cepas resistentes a los fármacos de primera línea alcanza al 25% de los nuevos casos en algunas regiones. Aunque España es considerada un país de baja incidencia, varios centenares de niños y adolescentes enferman de TB cada año. La importancia de la TB pediátrica ha sido minimizada durante años por la dificultad en confirmar el diagnóstico microbiológico y la escasa contagiosidad que asocia. Sin embargo, en los últimos 15 años, se han reportado mejoras relevantes en los informes epidemiológicos de la TB en niños y adolescentes, han surgido nuevos test inmunodiagnósticos, se dispone de estudios de biología molecular que permiten un diagnóstico microbiológico y una identificación de mutaciones asociadas a resistencia rápidos, han surgido nuevos fármacos antituberculosos de segunda línea, también en pediatría, y se han publicado ensayos clínicos que validan tratamientos acortados en algunos pacientes. Este documento, realizado por un grupo de expertos de la Sociedad Española de Infectología Pediátrica y la Sociedad Española de Neumología Pediátrica, actualiza y complementa las recomendaciones previas para el manejo diagnóstico y terapéutico del niño con TB en España, en base a las nuevas evidencias científicas disponibles. (AU)
According to WHO estimates, more than 1 million patients aged less than 15 years develop tuberculosis (TB) each year worldwide. In some regions, up to 25% of new TB cases are caused by drug-resistant strains. Although Spain is considered a low-incidence country, several hundred children and adolescents develop TB each year. The importance of paediatric TB has been minimized for years due to the lack of microbiological confirmation in many patients and because these patients are not usually contagious. Nevertheless, in the past 15 years there have been major improvements in the epidemiological reporting of TB in children and adolescents, new immunodiagnostic tests have been developed, molecular methods that allow rapid microbiological diagnosis and detection of variants associated with drug resistance have become available, novel second-line antituberculosis drugs have been discovered, including for paediatric use, and the results of clinical trials have validated shorter courses of treatment for some patients. This document, developed by a group of experts from the Sociedad Española de Infectología Pediátrica and the Sociedad Española de Neumología Pediátrica, updates and complements the previous guidelines for the diagnostic and therapeutic management of children with TB in Spain based on the newly available scientific evidence. (AU)
Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Child, Preschool , Child , Adolescent , Tuberculosis/diagnosis , Tuberculosis/drug therapy , Tuberculosis/epidemiology , Spain , Tuberculin Test , Drug Resistance, MicrobialABSTRACT
According to World Health Organization estimates, more than 1 million patients aged less than 15 years develop tuberculosis (TB) each year worldwide. In some regions, up to 25% of new TB cases are caused by drug-resistant strains. Although Spain is considered a low-incidence country, several hundred children and adolescents develop TB each year. The importance of paediatric TB has been minimized for years due to the lack of microbiological confirmation in many patients and because these patients are not usually contagious. Nevertheless, in the past 15 years there have been major improvements in the epidemiological reporting of TB in children and adolescents, new immunodiagnostic tests have been developed, molecular methods that allow rapid microbiological diagnosis and detection of variants associated with drug resistance have become available, novel second-line antituberculosis drugs have been discovered, including for paediatric use, and the results of clinical trials have validated shorter courses of treatment for some patients. This document, developed by a group of experts from the Sociedad Española de Infectología Pediátrica and the Sociedad Española de Neumología Pediátrica, updates and complements the previous guidelines for the diagnostic and therapeutic management of children with TB in Spain based on the newly available scientific evidence.
Subject(s)
Tuberculosis , Adolescent , Humans , Child , Tuberculosis/diagnosis , Tuberculosis/drug therapy , Antitubercular Agents/therapeutic use , SpainABSTRACT
Primary ciliary dyskinesia (PCD) is an autosomal recessive rare disease caused by an alteration of ciliary structure. Immunofluorescence, consisting in the detection of the presence and distribution of cilia proteins in human respiratory cells by fluorescence, has been recently proposed as a technique to improve understanding of disease-causing genes and diagnosis rate in PCD. The objective of this study is to determine the accuracy of a panel of four fluorescently labeled antibodies (DNAH5, DNALI1, GAS8 and RSPH4A or RSPH9) as a PCD diagnostic tool in the absence of transmission electron microscopy analysis. The panel was tested in nasal brushing samples of 74 patients with clinical suspicion of PCD. Sixty-eight (91.9%) patients were evaluable for all tested antibodies. Thirty-three cases (44.6%) presented an absence or mislocation of protein in the ciliary axoneme (15 absent and 3 proximal distribution of DNAH5 in the ciliary axoneme, 3 absent DNAH5 and DNALI1, 7 absent DNALI1 and cytoplasmatic localization of GAS8, 1 absent GAS8, 3 absent RSPH9 and 1 absent RSPH4A). Fifteen patients had confirmed or highly likely PCD but normal immunofluorescence results (68.8% sensitivity and 100% specificity). In conclusion, immunofluorescence analysis is a quick, available, low-cost and reliable diagnostic test for PCD, although it cannot be used as a standalone test.
ABSTRACT
El sueño es un mecanismo biológico necesario para mantener una buena salud. Mientras dormimos ocurren una serie de cambios fisiológicos. Desde el punto de vista ventilatorio, durante el sueño profundo aumenta el volumen corriente y se alargan los tiempos inspiratorios y espiratorios, se enlentece la frecuencia respiratoria manteniéndose la relación volumen/tiempo como en vigilia. El término trastornos respiratorios relacionados con el sueño se refiere a un grupo de problemas respiratorios que se exacerban durante el sueño. Algunas de estas patologías se manifiestan casi exclusivamente durante el sueño, como el síndrome de apneas-hipopneas del sueño, que es, sin duda, el trastorno respiratorio más frecuente a pesar de estar infradiagnosticado, o el síndrome de hipoventilación alveolar central congénito (a veces llamado maldición de Ondine). El término incluye también otras patologías, que, aunque están presentes durante todo el día, empeoran cuando el paciente está dormido, como ocurre con muchas enfermedades pulmonares obstructivas o restrictivas. Las alteraciones del sueño pueden ser la expresión de enfermedades respiratorias subyacentes, algunas de ellas con prevalencia elevada, como la obesidad o el reflujo gastroesofágico. Asimismo, los patrones anómalos del sueño pueden ser causa o consecuencia de alteraciones en el desarrollo cognitivo del niño y en su aprendizaje (AU)
Sleep is a biological mechanism essential to maintaining good health. A series of physiological changes takes place during sleep. From a ventilation point of view, during deep sleep, tidal volume increases, the inhalation and expiration phases become longer, and respiratory frequency slows, while the same volume/time ratio as in wakefulness is maintained. The concept of sleep-related respiratory disorders refers to a group of respiratory diseases that are aggravated during sleep. Some of these disorders are almost exclusively manifested during sleep, such as sleep apnea-hypopnea syndrome undoubtedly the most frequent respiratory disease despite being underdiagnosed and congenital central hypoventilation syndrome (also called Ondine's curse). However, this concept also encompasses other disorders that occur during the daytime since they worsen while patients are asleep, as seen in many obstructive or restrictive pulmonary diseases. Sleep disorders can be a manifestation of underlying diseases, some of which are highly prevalent such as obesity and gastroesophageal reflux. Likewise, abnormal sleep cycles may be a cause or a result of cognitive disorders and disturbances in children's learning processes (AU)
Subject(s)
Humans , Male , Female , Child , Sleep Apnea, Obstructive/diagnosis , Hypoventilation/diagnosis , Sleep Wake Disorders/diagnosis , Child Development , Sleep/physiologyABSTRACT
Sleep is a biological mechanism essential to maintaining good health. A series of physiological changes takes place during sleep. From a ventilation point of view, during deep sleep, tidal volume increases, the inhalation and expiration phases become longer, and respiratory frequency slows, while the same volume/time ratio as in wakefulness is maintained. The concept of "sleep-related respiratory disorders" refers to a group of respiratory diseases that are aggravated during sleep. Some of these disorders are almost exclusively manifested during sleep, such as sleep apnea-hypopnea syndrome -undoubtedly the most frequent respiratory disease despite being underdiagnosed- and congenital central hypoventilation syndrome (also called Ondine's curse). However, this concept also encompasses other disorders that occur during the daytime since they worsen while patients are asleep, as seen in many obstructive or restrictive pulmonary diseases. Sleep disorders can be a manifestation of underlying diseases, some of which are highly prevalent such as obesity and gastroesophageal reflux. Likewise, abnormal sleep cycles may be a cause or a result of cognitive disorders and disturbances in children's learning processes.
